ClinicalTrials.gg
CompletedNCT01864174Updated Nov 29, 2019Results posted

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

A Phase 4 interventional study of Metformin XR and Metformin IR in Type 2 Diabetes Mellitus, sponsored by Bristol-Myers Squibb. Completed at 156 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-29.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,736
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
8th of 287
1,736 · median 100
Started
2013
with 15 others
Phase 4
98 of 293
6 open now
Registered
178th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2013, is one of 98 in phase 4, and was the 178th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Men and women, aged ≥18 years old at time of enrollment
  • Treatment naive subjects with type 2 diabetes mellitus with inadequate glycemic ( ≥7.0% and ≤9.2% obtained at screening visit) control on diet and exercise alone
  • Women must have a negative serum or urine test within 24 hours prior to start of product

Exclusion criteria

Exclusion Criteria:

  • History of ketoacidosis, lactic acidosis or hyperosmolar non-ketonic coma
  • Symptoms of poorly controlled diabetes, including but not limited to marked polyuria and polydipsia with >10% weight loss during last 3 months
  • Serum creatinine ≥1.50 mg/dL (133 μmol/L) for male subjects; serum creatinine ≥1.40 mg/dL (124 μmol/L for female subjects)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,736 participants (actual)

Study arms

  • Active comparator
    Arm 1: Metformin XR and Placebo matching with Metformin XR

    Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks

    Drug: Metformin XR · Drug: Placebo matching with Metformin XR

  • Active comparator
    Arm 2: Metformin IR and Placebo matching with Metformin IR

    Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks

    Drug: Metformin IR · Drug: Placebo matching with Metformin IR

Interventions

  • Also known as: Glucophage XR

  • Also known as: Glucophage

  • DrugPlacebo matching with Metformin XR
  • DrugPlacebo matching with Metformin IR
06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in HbA1c

    Mean change in glycated hemoglobin (HbA1c) from baseline to Week 24 in the double-blind treatment period.

    Time frame: Baseline and Week 24

  2. Number of Participants With Death, Serious Adverse Events (SAEs), SAEs Related to Study Therapy, SAEs Leading to Discontinuation, Adverse Events (AEs) Related to Study Therapy, and AEs Leading to Discontinuation

    SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Treatment-related=having certain, probable, possible, or missing relationship to study drug. All listed events are treatment emergent, which is defined as nonserious and serious AEs with an onset from Day 1 of the double-blind treatment up to and including 4 days and 30 days respectively, after the last dose date of double-blind study. randomized.

    Time frame: Date of first dose (Day 1) up to 30 post last dose of study drug (approx. 28 weeks)

Secondary outcomes

  1. Mean Change in Fasting Plasma Glucose (FPG)

    The mean change in fasting plasma glucose (FPG) from baseline to Week 24 in the double-blind treatment period was assessed. The lack of glycemic control criteria for initiation of rescue medication during Week 12 to Week 24 was having a FPG \> 200 mg/dL (11.1 mmol/L). mg/dL = milligrams per deciliter; mmol/L = millimole per Liter

    Time frame: Baseline and Week 24

  2. Mean Change in Mean Daily Glucose (MDG)

    The mean change in Mean Daily Glucose (MDG) from baseline to Week 24 in the double-blind treatment period was assessed. Prior to the Day 1 visit (between Week -1 and Day 1) and in the week before the Week 24/Study Termination and Rescue or Early Treatment Termination visit, participants performed 7-point finger stick blood glucose monitoring (before and 2 hours after 3 meals per day, and at bedtime) for 3 consecutive days in order to determine their MDG.

    Time frame: Baseline and Week 24

  3. Percent of Participants With HbA1c < 7%

    Percent of participants achieving a therapeutic glycemic response (defined as HbA1c \< 7.0%) at Week 24 in the double-blind treatment period.

    Time frame: Week 24

07

Results

Posted Jul 21, 2017

Participant flow

1736 enrolled at 148 study sites in North America, Europe, and South Africa.Lead in period=794. Reasons not entered: 1 AE, 17 WC, 4 lost to FU, 3 NC, 911 SC, 4 ARS, 1 other. Adverse event=-AE, Withdrew consent=WC, Follow-up=FU, poor/non-compliance=NC, No longer met study criteria=SC, Administrative reason by sponsor=ARS.

Double Blind Treatment - All Treated
Participant flow — Double Blind Treatment - All Treated
MilestoneMetformin XRMetformin IR
Started283285
Completed268271
Not completed1514
Withdrew: Removed due to site non-compliance1514
Double Blind - Compliant Randomized
Participant flow — Double Blind - Compliant Randomized
MilestoneMetformin XRMetformin IR
Started268271
Completed245245
Not completed2326
Withdrew: Adverse event61
Withdrew: Subject request to discontinue treatment20
Withdrew: Subject withdrew consent45
Withdrew: Death10
Withdrew: Lost to follow-up310
Withdrew: Poor/non-compliance10
Withdrew: Other610
Off Treatment Follow-Up
Participant flow — Off Treatment Follow-Up
MilestoneMetformin XRMetformin IR
Started91
Completed61
Not completed30
Withdrew: Other20
Withdrew: Subject withdrew consent10

Outcome measures

PrimaryAdjusted Mean Change From Baseline in HbA1c

Mean change in glycated hemoglobin (HbA1c) from baseline to Week 24 in the double-blind treatment period.

Time frame:
Baseline and Week 24
Reported as:
Mean · percent
Adjusted Mean Change From Baseline in HbA1c
percentMetformin XRMetformin IR
Adjusted Mean Change From Baseline in HbA1c-0.93 ± 0.0485-0.96 ± 0.0480
Statistical analysis
  • Metformin XR vs Metformin IR · Mean difference (final values): 0.03 · 95% CI -0.10 to 0.17METFORMIN XR VS METFORMIN IR
SecondaryMean Change in Fasting Plasma Glucose (FPG)

The mean change in fasting plasma glucose (FPG) from baseline to Week 24 in the double-blind treatment period was assessed. The lack of glycemic control criteria for initiation of rescue medication during Week 12 to Week 24 was having a FPG \> 200 mg/dL (11.1 mmol/L). mg/dL = milligrams per deciliter; mmol/L = millimole per Liter

Time frame:
Baseline and Week 24
Reported as:
Mean · mg/dL
Mean Change in Fasting Plasma Glucose (FPG)
mg/dLMetformin XRMetformin IR
Mean Change in Fasting Plasma Glucose (FPG)-21.1 ± 1.803-20.6 ± 1.789
SecondaryMean Change in Mean Daily Glucose (MDG)

The mean change in Mean Daily Glucose (MDG) from baseline to Week 24 in the double-blind treatment period was assessed. Prior to the Day 1 visit (between Week -1 and Day 1) and in the week before the Week 24/Study Termination and Rescue or Early Treatment Termination visit, participants performed 7-point finger stick blood glucose monitoring (before and 2 hours after 3 meals per day, and at bedtime) for 3 consecutive days in order to determine their MDG.

Time frame:
Baseline and Week 24
Reported as:
Mean · mg/dL
Mean Change in Mean Daily Glucose (MDG)
mg/dLMetformin XRMetformin IR
Mean Change in Mean Daily Glucose (MDG)-24.68 ± 1.5813-27.05 ± 1.555
SecondaryPercent of Participants With HbA1c < 7%

Percent of participants achieving a therapeutic glycemic response (defined as HbA1c \< 7.0%) at Week 24 in the double-blind treatment period.

Time frame:
Week 24
Reported as:
Number · percent of participants
Percent of Participants With HbA1c < 7%
percent of participantsMetformin XRMetformin IR
Percent of Participants With HbA1c < 7%70.9 (65.5 to 76.3)72.0 (66.3 to 77.7)
PrimaryNumber of Participants With Death, Serious Adverse Events (SAEs), SAEs Related to Study Therapy, SAEs Leading to Discontinuation, Adverse Events (AEs) Related to Study Therapy, and AEs Leading to Discontinuation

SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Treatment-related=having certain, probable, possible, or missing relationship to study drug. All listed events are treatment emergent, which is defined as nonserious and serious AEs with an onset from Day 1 of the double-blind treatment up to and including 4 days and 30 days respectively, after the last dose date of double-blind study. randomized.

Time frame:
Date of first dose (Day 1) up to 30 post last dose of study drug (approx. 28 weeks)
Reported as:
Number · participants
Number of Participants With Death, Serious Adverse Events (SAEs), SAEs Related to Study Therapy, SAEs Leading to Discontinuation, Adverse Events (AEs) Related to Study Therapy, and AEs Leading to Discontinuation
participantsMetformin XRMetformin IR
Death10
SAE810
SAEs Related to Study Therapy11
SAEs Leading to Discontinuation01
AEs Related to Study Therapy3025
AEs Leading to Discontinuation107

Adverse events

Collected over From Day 1 up to 30 days post last dose (approx. 28 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Metformin XR—8/283 (2.8%)25/283 (8.8%)
Metformin IR—10/285 (3.5%)22/285 (7.7%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventMetformin XRMetformin IR
OverdoseInjury, poisoning and procedural complications2/2830/285
Hypocoagulable stateBlood and lymphatic system disorders1/2830/285
Angina unstableCardiac disorders1/2830/285
Upper gastrointestinal haemorrhageGastrointestinal disorders1/2830/285
CholelithiasisHepatobiliary disorders1/2830/285
Delayed recovery from anaesthesiaInjury, poisoning and procedural complications1/2830/285
Malignant melanoma in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2830/285
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2830/285
Cerebral haemorrhageNervous system disorders1/2830/285
DiplopiaEye disorders0/2831/285
Most frequent other events
Most frequent other events
EventMetformin XRMetformin IR
DiarrhoeaGastrointestinal disorders25/28322/285

Baseline characteristics

All Treated Data Set (n=568) are the randomized participants who received at least 1 dose of study drug during the double blind treatment period (up to rescue). 29 participants were excluded from the baseline Randomized Data Set; therefore, the number of participants included in the baseline population is 539. n = number of evaluable participants

Age, Continuous
Age, Continuous(years)Metformin XRMetformin IRTotal
Mean56.8 ± 10.6955.3 ± 10.3456.0 ± 10.53
Age, Customized
Age, Customized(participants)Metformin XRMetformin IRTotal
< 65 years198226424
>= 65 years7045115
Sex: Female, Male
Sex: Female, Male(Participants)Metformin XRMetformin IRTotal
Female122122244
Male146149295
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Metformin XRMetformin IRTotal
White227225452
Black or African American221941
Asian172037
Other279
08

Study locations

156 sites
  • Central Alabama Research
    Birmingham, Alabama 35209, United States
  • Terence T. Hart, Md
    Muscle Shoals, Alabama 35662, United States
  • Clini Res Advantage Desert Clin Res, Llc
    Mesa, Arizona 85213, United States
  • Clinical Res Advantage Central
    Phoenix, Arkansas 85020, United States
  • Marin Endocrine Care And Research, Inc.
    Greenbrae, California 94904, United States
  • Torrance Clinical Research Institute Inc.
    Lomita, California 90717, United States
  • Actca
    Los Angeles, California 90017, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • R. Srinivasan, M.D., Inc.
    Monterey Park, California 91754, United States
  • Diabetes Medical Center Of California
    Northridge, California 91325, United States
  • Valley Clinical Trials
    Northridge, California 91325, United States
  • Center For Clinical Trials Of Sacramento, Inc.
    Sacramento, California 95823, United States
  • Clinical Research Advantage
    Colorado Springs, Colorado 80906, United States
  • Clinical Research Advantage
    Colorado Springs, Colorado 80909, United States
  • Colorado Springs Family Practice
    Colorado Springs, Colorado 80909, United States
  • Clinical Research Advantage, Inc/Co Springs Health Partners, Briar
    Colorado Springs, Colorado 80920, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32258, United States
  • Family Care Partners
    Jacksonville, Florida 32277, United States
  • Omega Research Consultants, Llc
    Orlando, Florida 32804, United States
  • Palm Harbor Medical Associates
    Palm Harbor, Florida 34684, United States
  • Gulfcoast Medical Research Center, Llc
    Tampa, Florida 33607, United States
  • Cedar-Crosse Research Ctr
    Chicago, Illinois 60607, United States
  • Clinical Research Advantage, Inc./Family Medicine Associates
    Evansville, Indiana 47725, United States
  • American Health Network Of In Llc
    Muncie, Indiana 47304, United States
  • Columbia Medical Practice
    Columbia, Maryland 21045, United States
  • Centennial Medical Group
    Elkridge, Maryland 21075, United States
  • Drs. Rodbard And Dempsey
    Rockville, Maryland 20852, United States
  • Ny Clinical Trials
    New York, New York 10018, United States
  • White Oak Family Physicians, Pa
    Asheboro, North Carolina 27203, United States
  • Metrolina Internal Medicine
    Charlotte, North Carolina 28204, United States
  • Medical Research Unlimited, Inc.
    Cincinnati, Ohio 45242, United States
  • Lion Research
    Norman, Oklahoma 73069, United States
  • Lynn Institute of Norman
    Norman, Oklahoma 73069, United States
  • Integrated Medical Group Pc / Fleetwood Medical Assoc.
    Fleetwood, Pennsylvania 19522, United States
  • Palmetto Clinical Trial Services Llc
    Fountain Inn, South Carolina 29644, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • Dallas Diabetes & Endocrine Center
    Dallas, Texas 75230, United States
  • Covenant Clinical Research, Pa
    San Antonio, Texas 78229, United States
  • Independence Family Medicine
    Virginia Beach, Virginia 23455, United States
  • Local Institution
    Edmonton, Alberta T5A 4L8, Canada
  • Local Institution
    Winnipeg, Manitoba R2V 4W3, Canada
  • Local Institution
    Brampton, Ontario L6T 0G1, Canada
  • Local Institution
    Burlington, Ontario L7M 4YI, Canada
  • Local Institution
    Collingwood, Ontario L9Y 1W3, Canada
  • Local Institution
    London, Ontario N6H 0G6, Canada
  • Local Institution
    Newmarket, Ontario L3Y 5G8, Canada
  • Local Institution
    Toronto, Ontario M9V 4B4, Canada
  • Local Institution
    Toronto, Ontario M9W 4L6, Canada
  • Local Institution
    London, N5W 6A2, Canada
  • Local Institution
    Quebec, G1N 4V3, Canada
  • Local Institution
    Brno, 636 00, Czechia
  • Local Institution
    Ceske Budejovice, 370 01, Czechia
  • Local Institution
    Krnov, 794 01, Czechia
  • Local Institution
    Liberec, 460 01, Czechia
  • Local Institution
    Litomysl, 570 14, Czechia
  • Local Institution
    Novy Jicin, 741 01, Czechia
  • Local Institution
    Ostrava - Kuncice, 719 00, Czechia
  • Local Institution
    Praha 10, 100 00, Czechia
  • Local Institution
    Praha 1, 11694, Czechia
  • Local Institution
    Praha 5, 15000, Czechia
  • Local Institution
    Aschaffenburg, Bayern 63739, Germany
  • Local Institution
    Munster, Nordrhein-Westfalen 48145, Germany
  • Local Institution
    Leipzig, Saxony 04249, Germany
  • Local Institution
    Berlin, 12157, Germany
  • Local Institution
    Heidelberg, 69115, Germany
  • Local Institution
    Leipzig, Germany
  • Local Institution
    Lohne, 32584, Germany
  • Local Institution
    Myen, 56727, Germany
  • Local Institution
    Papenburg, D-26871, Germany
  • Local Institution
    Pirna, 01796, Germany
  • Local Institution
    Pecs, Baranya 7623, Hungary
  • Local Institution
    Szigetvar, Baranya 7900, Hungary
  • Local Institution
    Satoraljaujhely, Borsod-Abauj-Zemplen 3980, Hungary
  • Local Institution
    Hodmezvasarhely, Csongrad 6800, Hungary
  • Local Institution
    Nyiregyhaza, Szabolcs-Szatmar-Bereg 4400, Hungary
  • Local Institution
    Nyiregyhaza, Szabolcs-Szatmar-Bereg 4405, Hungary
  • Local Institution
    Budapest, 100036, Hungary
  • Local Institution
    Budapest, 1033, Hungary
  • Local Institution
    Budapest, 1083, Hungary
  • Local Institution
    Budapest, 1097, Hungary
  • Local Institution
    Budapest, 1183, Hungary
  • Local Institution
    Budapest, 1212, Hungary
  • Local Institution
    Csorna, 9300, Hungary
  • Local Institution
    Debrecen, 4025, Hungary
  • Local Institution
    Kecskemet, 6000, Hungary
  • Local Institution
    Mosonmagyarovar, 9200, Hungary
  • Local Institution
    Nagykanizsa, 8800, Hungary
  • Local Institution
    Oroshaza, 5900, Hungary
  • Local Institution
    Szekesfehervar, 8000, Hungary
  • Local Institution
    Szentes, 6600, Hungary
  • Local Institution
    Szobathely, H-9700, Hungary
  • Local Institution
    Gdansk, Pomorskie 80-546, Poland
  • Local Institution
    Katowice, Slaskie 40-752, Poland
  • Local Institution
    Bialystok, 15-276, Poland
  • Local Institution
    Bialystok, 15-435, Poland
  • Local Institution
    Krakow, 31-024, Poland
  • Local Institution
    Krakow, 31261, Poland
  • Local Institution
    Lublin, 20-090, Poland
  • Local Institution
    Lublin, 20-538, Poland
  • Local Institution
    Poznan, 61-655, Poland

Showing the first 100 of 156 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Jun 2016, 35 months.

Results were first posted in Jul 2017, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 35 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2013
First posted
May 29, 2013
StartActual
Jun 20, 2013
Primary completionActual
Jun 1, 2016
CompletionActual
Jun 1, 2016
Results first posted
Jul 21, 2017
Last update
Nov 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01864174
Responsible party
Sponsor
First posted
May 29, 2013
Start date
Jun 20, 2013
Primary completion
Jun 1, 2016
Completion
Jun 1, 2016
Results posted
Jul 21, 2017
Last update
Nov 29, 2019

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion